
    
      This is an open-label, pilot study to explore the efficacy of chloroquine in terminating
      persistent AF within 2 weeks of drug administration and assess its potential role as a
      pharmacological cardioversion agent for the management of AF. Subjects will be followed for 2
      weeks from the start of drug administration to study drug termination.
    
  